Microbial transmission from mothers with obesity or diabetes to infants: an innovative opportunity to interrupt a vicious cycle
- 3.8k Downloads
Maternal obesity and diabetes dramatically increase the long-term risk for obesity in the next generation, and pregnancy and lactation may be critical periods at which to aim primary prevention to break the obesity cycle. It is becoming increasingly clear that the gut microbiome in newborns and infants plays a significant role in gut health and therefore child development. Alteration of the early infant gut microbiome has been correlated with the development of childhood obesity and autoimmune conditions, including asthma, allergies and, more recently, type 1 diabetes. This is likely to be due to complex interactions between mode of delivery, antibiotic use, maternal diet, components of breastfeeding and a network of regulatory events involving both the innate and adaptive immune systems within the infant host. Each of these factors are critical for informing microbiome development and can affect immune signalling, toxin release and metabolic signals, including short-chain fatty acids and bile acids, that regulate appetite, metabolism and inflammation. In several randomised controlled trials, probiotics have been administered with the aim of targeting the microbiome during pregnancy to improve maternal and infant health but the findings have often been confounded by mode of delivery, antibiotic use, ethnicity, infant sex, maternal health and length of exposure. Understanding how nutritional exposure, including breast milk, affects the assembly and development of both maternal and infant microbial communities may help to identify targeted interventions during pregnancy and in infants born to mothers with obesity or diabetes to slow the transmission of obesity risk to the next generation. The aim of this review is to discuss influences on infant microbiota colonisation and the mechanism(s) underlying how alterations due to maternal obesity and diabetes may lead to increased risk of childhood obesity.
KeywordsDiabetes Infant Maternal Microbiome Obesity Pregnancy Review
Farnesoid X receptor
Gestational diabetes mellitus
G protein-coupled receptor
Gestational weight gain
Human milk oligosaccharide
Lactobacillus rhamnosus strain GG
Non-alcoholic fatty liver disease
Randomised controlled trial
Short-chain fatty acid
G protein-coupled BA receptor 1
Introduction: gestational diabetes and obesity affect the health of both mother and infant
The developmental origins of health and disease (DoHAD) hypothesis, now substantiated by extensive research in animals and humans, suggests that both maternal nutrient deficiency and nutrient excess in utero and in early infancy programs a susceptibility to metabolic disease later in life [1, 2, 3]. The importance of minimising risks associated with maternal obesity and/or diabetes is no longer limited to improving the immediate pregnancy outcomes for mother and infant but, even more challenging, includes improving the long-term metabolic health of the affected offspring .
Maternal obesity and diabetes are consistently among the most powerful predictors of childhood obesity  and other adverse health conditions, such as type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and the metabolic syndrome, now emerging in children as young as 6 years of age . Maternal Western-style diet (WSD) and insulin resistance in non-human primates (NHPs) promote lipotoxicity in the fetal liver  and NAFLD-like changes that persist in the offspring despite weaning to a healthy diet . In human infants, using nuclear magnetic resonance spectroscopy, newborns from mothers with gestational diabetes mellitus (GDM) and obesity show evidence of increased intrahepatic fat at birth , potentially increasing the risk for NAFLD in adolescence . Changes in behaviour, including appetite, anxiety and aggression, as well as neurological neurotransmitter pathways, have been observed in 1-year-old juvenile NHPs exposed to a maternal WSD, suggesting multiple systems are affected . Recent data in humans also indicate that maternal obesity increases the capacity for umbilical cord mesenchymal stem cells to undergo adipogenesis, markers of which correlate with infant adiposity . Consequently, there is an enormous public health need to target underlying dietary or metabolic factors in mothers with obesity or diabetes to prevent early-life obesity, NAFLD and diabetes risk in the next generation .
Cross-fostering A technique in animal research in which offspring are removed from the biological mother at birth and breastfed by a surrogate mother
Dysbiosis An imbalance of or an unhealthy change in, the normal composition of microbes in a particular microbiome
Endotoxin Component of the outer membrane of Gram-negative bacteria known to elicit a strong immune response when in systemic circulation (endotoxaemia) also known as lipopolysaccharide
Enterohepatic circulation Circulation of substances such as bile acids, from the liver into bile, secretion into the small intestine, absorption by enterocytes and transportation back to the liver
Epigenome The chemical modification of the DNA (genome) (e.g. the attachment of a methyl group) to alter gene expression
Glycans Compounds consisting of a large number of monosaccharides linked glycosidically also known as polysaccharides glycans may also refer to the carbohydrate portion of a glycoconjugate (also known as glycoprotein glycolipid, proteoglycan or oligosaccharide)
Gnotobiotic mice Mice colonised by a known set of gut bacteria or no gut bacteria (germ-free) and raised in an aseptic environment
Inflammasome A multiprotein complex that activates caspases and leads to the formation and secretion of proinflammatory cytokines as a component of the innate immune system
Lamina propria Connective tissue layer of the intestine that together with the epithelium constitutes the gut mucosa
Lipopolysaccharide See Endotoxin
Microbiome The community of microorganisms found in a particular environment such as a part of the body
Oligosaccharide Saccharide polymer containing a small number of monosaccharides
Prebiotics Substances used to promote the growth of microorganisms often these are indigestible carbohydrates that are used as energy substrate for gut microbes
Probiotics Live bacteria and yeasts that are beneficial to a host
Short-chain fatty acid Saturated aliphatic organic acids with one to six carbons end-product of dietary fermentation by anaerobic microbiota
Toll-like receptor A component of the innate immune system that recognises structurally conserved motifs that are expressed exclusively on microbial pathogens to initiate an inflammatory response
Development of the infant microbiome and childhood obesity risk
Pregnancy and the maternal microbiome
Each individual’s gut microbiome consists of a unique pattern of microbes that is determined by both diversity (different strains of bacteria) and abundance (quantity of each strain). Mothers share their microbes and microbiome metabolites with the fetus in utero, during delivery and during lactation; the composition of the microbiome is shaped by the environment including diet, maternal health status and metabolism, mode of delivery, gestational weight gain (GWG), genetics and use of antibiotics.
The maternal gut microbiota differs between women with normal weight and obesity particularly in the latter half of pregnancy, with overweight women demonstrating increases in the Firmicutes phylum (Staphylococcus) as well as increases in some Proteobacteria (Escherichia coli) . Furthermore, these differences are associated with increased neonatal birthweight [21, 22]. One mechanism by which maternal microbes in obesity could affect the developing fetus is through elevated levels of microbe-derived plasma endotoxin; this may increase gut translocation of bacteria-derived products across the intestinal mucosa, which could contribute to systemic and placental inflammation and insulin resistance . In 2012, Koren et al demonstrated changes in the maternal gut microbiome composition from the first to the third trimester of pregnancy . When pooled stool samples from either trimester were inoculated into gnotobiotic mice, stool from the third trimester was associated with excess weight gain and inflammation compared with mice receiving stool from women in their first trimester. However, this pregnancy-related change in microbe composition has been challenged recently by DiGiulio et al  who, by repeated sampling throughout gestation, demonstrated that vaginal, gut and oral cavity microbiota remained relatively stable during and after pregnancy (except in those who experienced preterm delivery). These discrepant findings require independent confirmation and may be explained by heterogeneity in BMI, age, ethnicity, genetics, lifestyle, degree of maternal insulin resistance, gestational age and especially by differences in the maternal diet or supplementation, which could markedly affect microbiome composition .
Mode of delivery affects the infant microbiome and obesity risk
Although the founding microbiota composition in infants largely reflects maternal transfer during birth, the mode of delivery affects postnatal assembly of the microbiota and thereby altering resistance to pathogen invasion, immune stimulation and other important developmental cues early in life . Infants born by vaginal delivery are colonised by microbes resident in the birth canal and the mother’s gastrointestinal tract, whereas infants born by Caesarean delivery are initially colonised by skin flora [26, 27]. In breastfed infants delivered at full term without medical interventions, the gut microbiota at 4 days is dominated by Gammaproteobacteria and some Staphylococcus species, followed by subsequent Bifidobacterium colonisation . In babies born via Caesarean delivery, infants’ stool revealed a decrease in Bacteroidetes phylum, Bifidobacterium and Lactobacillus species and a rise in Clostridium species, as well as an overall reduction in microbiome diversity; these differences persisted, in some cases even at 2 years of age [26, 28].
Differences in the early microbiome may have metabolic consequences, as Caesarean delivery is associated with a 46% increase in obesity risk at 7 years of age  and a 20% increased risk in development of type 1 diabetes compared with children born vaginally . One study found that while most infants had acquired high levels of the genus Bifidobacterium by the age of 6 months, this acquisition was delayed in infants born via Caesarean delivery . Furthermore, the abundance of these microbes inversely correlated with infant adiposity at the age of 18 months, demonstrating that the correlation of mode of delivery with infant adiposity may be driven by microbiome composition . However, other confounding variables associated with Caesarean delivery risk, such as peripartum antibiotics, maternal obesity, glucose intolerance and insulin resistance, could independently influence the infant microbiome and obesity risk. Increased childhood BMI following Caesarean delivery is more pronounced in offspring of mothers with obesity , suggesting that gestational risk factors, mode of delivery and postnatal environment may contribute to shaping future obesity risk during this highly susceptible period of life.
While maternal vaginal and intestinal microbes are important, as they are the sites of vertical microbial transmission to the newborn during vaginal delivery, a recent paradigm shift suggests that the womb is not sterile and microbial exposure may begin in utero. The placenta and amniotic fluid have been reported to serve as potential sources of intrauterine microbial transmission from the mother to the developing fetus [31, 32]. However, the potential for contamination and the low biomass of microbes in these sources suggest that more research is needed to understand how they affect infant immunity and gut development.
Maternal diet and infant breastfeeding shapes the microbial community: impact on immunity and metabolism
In humans, the composition of breast milk influences the development of intestinal permeability, energy retention capacity and autoimmunity and may differ according to maternal obesity status and maternal diet . Accumulating evidence suggests that exclusive breastfeeding is associated with lower risk of paediatric obesity [34, 35] and that this protection may be even greater in women with obesity who breastfeed their infants for at least 6 months . However, breastfeeding-induced protection against obesity in offspring is not universal across all lactating mothers and remains poorly characterised .
Cross-fostering studies in mice in which offspring of lean dams were nursed by obese dams suggested that maternal obesity had distinct effects on the hormonal, nutritional and microbial composition of milk that were associated with a NAFLD phenotype as well as with increased body weight, plasma insulin and proinflammatory cytokines in offspring . However, it is important to note that in mouse studies, the effect of coprophagy (the eating of faeces) cannot be ruled out as a contributing factor in offspring response to obese dam exposure. Similarly, offspring born to mothers fed a WSD and switched to normal chow diet after weaning had worse outcomes than those offspring whose mothers were only exposed to standard low-fat diet with respect to infection, autoimmunity and allergic sensitisation, which often precede the development of obesity . These maternal WSD effects were linked to alterations of the offspring gut microbiome, suggesting that excess dietary fat consumption during pregnancy and lactation can have effects on offspring immunity and gut barrier function that persist into later life. However, very few studies take into consideration differences in breast milk related to maternal phenotype and even fewer link these to their impact on infant microbiome and infant gut function. The factors involved in human milk transfer of obesity risk remain poorly understood.
In humans, breast milk serves as a principal source of important immune and growth factors necessary for initial microbial colonisation. Human milk glycans are a large and diverse group of polysaccharides that include free human milk oligosaccharides (HMOs), glycoproteins, glycopeptides and glycolipids capable of enriching populations of Bifidobacteria . HMOs are complex sugars that resist digestion by the infant’s stomach and are metabolised by selective intestinal microbiota. The metabolism of HMOs can lead to the production of short-chain fatty acids (SCFAs), which may have metabolic influences (discussed below). It is generally accepted that HMOs have significant prebiotic effects, serving as a source of energy and nutrients that enable desired bacteria to colonise the infant intestinal tract . The type of oligosaccharides that infants receive from their mothers depends on the mother’s genotype and phenotype [33, 41] but the amount may be variable, particularly given that mothers with obesity and diabetes have difficulties breastfeeding. A more in-depth coverage of milk glycans and the infant gut microbiome is beyond the scope of this review but this topic is covered extensively by Bode .
The most common microbes found in human breast milk, but in relatively low abundance, are from the genera Bifidobacterium and Lactobacillus , similar to the microbes found in the infant gut. This suggests that breast milk microbiota, albeit at very low concentrations, can be transferred to the infant gut, although this finding is not universal . Similar to the gut microbiome, breast milk microbial communities from mothers with obesity or excessive GWG were less diverse and had a higher relative abundance of the groups Lactobacillus and Staphylococcus and reduced Bifidobacterium at 6 months post delivery . Moreover, breast milk from women with obesity contains high levels of metabolic and inflammatory markers, such as leptin, insulin, glucose, IL-6 and TNFα, compared with milk from women with normal weight . These changes, in addition to changes in antioxidant and microbial status, may be important factors in shaping the early infant gut microbiome .
Medium-chain saturated and long-chain unsaturated fatty acids present in breast milk have also been shown to have antimicrobial properties , suggesting that higher triacylglycerol hydrolysis or circulating fatty acids in obesity might have an impact on microbial colonisation in the infant. Studies are needed to establish whether human milk lipids have an antimicrobial effect in the offspring and whether they play a role in the development of the infant microbiome. To date very little is known about the contents of breast milk from women with diabetes [48, 49]. Compared with breastfed infants, the diversity of the genus Bifidobacterium was found to be decreased in formula-fed infants  and this was associated with increased adiposity at 18 months . Interestingly, formula-fed infants have greater diversity of gut microbial communities relative to breastfed infants and, functionally, these infants have higher proportions of proinflammatory Gammaproteobacteria  which may suggest delayed gut maturation. It is important to note that thus far studies have not addressed the effect of breast milk volume consumed, duration of breastfeeding or the impact of formula supplementation on the development of the infant gut microbiome. Given the beneficial attributes of breast milk in establishing the early microbiome, a deviation from the normal composition of breast milk may be associated with an increased risk of obesity and inflammatory conditions. Thus, while breastfeeding is strongly recommended as the best source of nutrition for a newborn, it is clear that not all breast milk is the same. This raises the question of whether and how changes in diet or pre- or probiotics in lactating women with obesity or diabetes can affect the developing gut microbiome of the newborn (discussed below).
Early antibiotic exposure increases the risk for obesity
Retrospective studies of antibiotic exposure at various windows of time during the first 2 years of life found that broad-spectrum treatment is associated with childhood obesity [51, 52]. Children born to mothers who were given antibiotics during the second or third trimester of pregnancy had an 84% higher risk of obesity at age 7 years; however, first-trimester antibiotics had no effect . Animal studies have suggested that there is a critical window during which alteration of the gut microbiota can influence future health. Antibiotic treatment given to neonatal mice just prior to or immediately following birth through weaning resulted in enhanced susceptibility to allergic asthma, while the same treatment in adult mice had no effect [53, 54, 55]. Likewise, mice exposed to prenatal antibiotics had increased body fat percentage and increased expression of adipogenic targets, including peroxisome proliferator-activated receptor γ and fatty acid binding protein 2. Moreover, in mice, a HFD combined with maternal antibiotic use exacerbated changes in body mass and hyperinsulinaemia in the offspring, suggesting that maternal obesity may compound the effect of antibiotics on disruption of the microbiome and downstream metabolic outcomes . Studies of infant postnatal antibiotic exposure in the first 6–12 months of life have found an association between antibiotic use and elevated weight and central adiposity as early as 24 months and up to 9 years of age regardless of maternal weight status [52, 56, 57]. These studies point to the ability of both maternal microbiome and early infant antibiotic exposure to program metabolic pathways in infants. The early gut microbiome and the immune system is reviewed more comprehensively by Maynard et al .
The microbiome and GDM
GDM is a growing problem and has a current prevalence of 9.2% in the USA  and 2–6% in Europe . The characterisation and role of microbiomes of women with GDM and their offspring are understudied. Data characterising intestinal microbiota in patients with type 2 diabetes showed that in addition to reduction of the Firmicutes phylum, the ratio of Bacteroidetes to Firmicutes correlated positively and significantly with plasma glucose concentration but not with BMI . Thus, bacterial species, specific for type 2 diabetes rather than obesity, can be considered as a separate signature altered by hyperglycaemia. More recently, the stool microbiota of insulin-resistant women with a history of GDM was characterised at 3–16 months postpartum and compared with that of normoglycaemic postpartum controls . These authors found that a subset of individuals with former GDM had relatively higher abundance of the Prevotellaceae family despite no apparent differences in diet compared with the control group. Additionally, at the phylum level, the former-GDM group had reduced abundance of Firmicutes, similar to the situation in type 2 diabetes. A role for Prevotella in mucin degradation in the gut  suggests that changes in gut health could be present in individuals who have high levels of insulin resistance, but this hypothesis has not been tested directly in individuals matched for similar BMI, race or breastfeeding status. In one study, offspring of women with diabetes, the meconium (the first intestinal discharge of a newborn) demonstrated an increased within-sample diversity and Bacteroidetes relative abundance compared with meconium from infants born to mothers without diabetes . However, the shift in meconium microbes was most apparent in those with pre-pregnancy diabetes, not GDM. The authors of this study hypothesised that certain conditions, such as pre-existing diabetes, may make microbes more transmissible in utero ; however, cross-fostering studies in rats have pointed to a specific role of breast milk in the transfer of GDM morbidity to offspring, particularly on neurological development . Although correlations between GDM and infant outcomes exist, the gut microbial shifts in GDM remain to be characterised before mechanisms of cause and effect on infant health can be elucidated.
Mechanisms for microbiome-induced metabolic disorders
SCFAs have recently emerged as pivotal regulators of host metabolism and immunity. SCFAs are gut microbiome byproducts, mainly acetates, propionates and butyrates, produced through anaerobic fermentation of indigestible dietary-fibre carbohydrates [65, 66]. SCFAs are absorbed and used by colonocytes (butyrate) and peripheral tissues (acetate) for energy, or may act as substrates for lipogenesis (acetate), gluconeogenesis (propionate) or regulation of cholesterol synthesis (propionate) in the liver. The hypothesis that dysbiosis may result in increased energy harvest was tested in subjects with normal weight and obesity that were fed the same diet for 3 days which led to increased energy retention of ∼630 kJ (∼150 kcal) in individuals with obesity and increased abundance of members of the Firmicutes phylum and reduced abundance of Bacteroidetes in stool samples in response to various diets . This shift was also associated with elevated SCFAs. Faecal metabolites in overweight children support this hypothesis since overweight as opposed to normal-weight children have lower levels of intermediate metabolites such as lactate, yet higher levels of butyrate, which is the byproduct of lactate-utilising microbiota, suggesting extensive substrate utilisation. In addition to increased energy extraction from the diet, SCFA metabolites can also influence levels of satiety hormone which could lead to altered food intake. Another mechanism by which SCFAs alter host physiology is through modification of immune cells in the gut. SCFAs upregulate colonic T regulatory (Treg) cells and render lamina propria macrophages hyporesponsive to normal gut microbes through the downregulation of proinflammatory effectors, shifting the cells toward an anti-inflammatory phenotype [66, 68].
Although levels of SCFAs have been reported to be elevated in faecal samples from individuals with obesity , it remains to be seen whether this is a cause of or response to the metabolic and inflammatory shifts in the microbiome. Knockdown of the SCFA receptors, namely G protein-coupled receptors (GPR40, GPR41 and GPR43), has led to inflammation, glucose intolerance and diet-induced obesity in mouse models . Moreover, studies of SCFAs have demonstrated beneficial metabolic effects when delivered enterally . In pregnant mice, supplementation with butyrate reduced maternal proinflammatory factors TNFα and IL-1β as well as weight gain, plasma glucose, insulin, triacylglycerol and cholesterol ; these effects may have been be due to butyrate inhibiting the inflammation and lipolysis generated by the interaction of adipocytes and macrophages . Furthermore, dietary butyrate ameliorated HFD-induced pancreatic beta cell dysfunction, as manifested by increased insulin storage, beta cell size, mass and apoptosis . SCFAs also act as important microbial signals to remodel the intestinal microbial community through activation of the inflammasome , thereby helping prevent chronic intestinal inflammatory responses to microbes and their products. Finally, the discovery of uteroplacental GPR41 and GPR43 receptors and their role in the inflammatory processes of labour could provide a path by which SCFAs influence fetal programming through their action on the placenta .
Recent studies have shown that microbes affect a diverse set of epigenetic factors, including DNA methylation, histone modification, chromatin-associated complexes and non-coding RNAs, to alter chromatin structure and gene expression . SCFAs have been reported to influence the epigenome; specifically, butyrate is recognised as a potent histone deacetylase inhibitor [66, 77]. Butyrate exerts an anti-inflammatory effect in mice by promoting Treg cell differentiation through an increase in histone H3 acetylation, which corresponds to increased Foxp3 mRNA expression [78, 79]. The microbiota in mice is also required to modulate the expression of Toll-like receptors 2 and 4 in the colon through epigenetic mechanisms . Interestingly, a recent pilot study correlated pregnant women with either Firmicutes or Bacteroidetes as a dominant group with differential DNA methylation profiles of gene promoters involved in lipid metabolism, obesity and inflammation in whole blood collected from the same women at 6 months postpartum , suggesting a relationship between microbes, or their products, and host epigenetic regulation.
Another important function of the gut microbiome that may affect infant physiology is the metabolism of primary bile acids (BAs) to secondary BAs in the small intestine. While ∼95% of secreted BAs is reabsorbed from the small intestine via the enterohepatic circulation pathway, ∼5% reaches the colon, where they are excreted. The primary BAs cholic acid and chenodeoxycholic acid are synthesised from cholesterol in the liver and conjugated to taurine or glycine to form bile salts before secretion into the duodenum where the bile assists in lipid digestion . Bacterial salt hydrolase deconjugates and dehydroxylates primary BAs to form secondary BAs, most commonly deoxycholic acid and lithocholic acid . Secondary BAs activate nuclear farnesoid X receptors (FXRs) in the liver, which regulate liver BA synthesis  and G protein-coupled BA receptor 1 (GPBAR1/TGR5) in the gut; this enhances secretion of glucagon-like peptide-1, which potentiates glucose-induced insulin secretion from beta cells . The beneficial effects of BA signalling via FXR and TGR5 also include attenuation of proinflammatory innate immune responses in a mouse model of NAFLD , lipopolysaccharide (LPS)-induced hepatic damage and inflammation  and inflammatory bowel disease . Conversely, there is evidence that excess BAs may influence microbiota composition through their strong antimicrobial activity. In mice, overfeeding with BAs induced changes similar to those seen with a HFD, including a shift from Bacteroidetes to Firmicutes (specifically the Clostridia and Erysipelotrichia classes) . The role of microbiome development and BA production in early life on glucose homeostasis and inflammation warrants further investigation.
Prevention and intervention with pre- and probiotics in mothers and infants
The use of pre- and probiotics has been shown to rapidly modify the microbial community and reduce (at least temporarily) adiposity and chronic inflammation in animal models of obesity and in limited human studies [89, 90, 91]. There have only been a handful of randomised controlled trials (RCTs) that examined the effects of probiotics administered during pregnancy with the aim of improving insulin sensitivity and reducing GDM diagnosis, with limited success. In one RCT either Bifidobacterium lactis alone or B. lactis plus Lactobacillus rhamnosus GG (LGG) probiotic was administered to pregnant women 14 days before a scheduled Caesarean delivery . Both treatments (compared with placebo) were found to decrease the expression of Toll-like receptor genes in the placenta and meconium of neonates, suggesting that in utero microbial exposure can alter the fetal innate immune system development. A Finnish study randomised 256 women during their first trimester of pregnancy into a control or dietary intervention group . The intervention group received intensive dietary counselling (increased fibre, less fat) provided by a nutritionist and were further randomised, double-blind, to receive a daily LGG and B. lactis probiotic that continued until the end of exclusive breastfeeding (average 3.4 months) postpartum. The infants were followed up at 24 months of age. Dietary counselling combined with probiotics decreased the frequency of GDM from 36% in the diet/placebo group to 13%. Despite lowering the risk of GDM, there were no significant differences in birthweight among groups after controlling for maternal BMI, smoking, length of gestation or infant growth over 24 months. This study lacked confirmation of changes in maternal or infant microbes following probiotic consumption. Interestingly, the risk of central adiposity in mothers at 6 months postpartum, defined as waist circumference 80 cm or more, was lower in women in the diet/probiotics group compared with the control/placebo group, with no effect seen after dietary intervention alone .
In a more recent RCT 175 pregnant women with an early pregnancy BMI of 30.0–39.9 kg/m2 were assigned to receive either a daily Lactobacillus salivarius probiotic or a placebo capsule from 24 to 28 weeks of gestation in addition to routine antenatal care . From pre-intervention to post-intervention, comparing groups there were no changes in fasting glucose, incidence of GDM or neonatal anthropometric measures . However, it is possible that the differences between studies may be due to differences in timing, duration and type of probiotic supplementation used, as well as a lack of analysis of the potential dietary influence on probiotic effects, rather than a lack of probiotic capacity to effect maternal obesity and GDM.
Although studies of maternal probiotic supplementation have not found differences in infant anthropomorphic outcomes [93, 95, 96], some studies have reported differences in infant gut microbial composition [96, 97, 98]. An RCT involving 122 mother–infant pairs at high risk of developing allergic disease found that daily LGG and B. lactis supplementation from 36 weeks gestation to delivery resulted in higher Bifidobacterium colonisation in the infant at 90 days of life despite the lack of LGG in maternal milk samples 1 month postpartum . A retrospective study of six women taking LGG from 30–36 weeks gestation until delivery found that in vaginally delivered infants, colonisation of LGG persisted up to 6 months postpartum . Interestingly, a subset of infants remained colonised up to 24 months despite a lack of maternal LGG supplementation at 1 month postpartum. However, anthropometric and metabolic outcomes were not assessed in the infants. Of note, prenatal LGG administration, while modulating Bifidobacterium levels, did not result in an increase in overall infant microbiome diversity at 7 days of life . While these studies cumulatively support the ability of maternal probiotic supplementation to alter the infant gut microbiome independent of direct vertical transmission of microbes, the effect of supplement timing during gestation, characterisation of these alterations, what specific factor(s) influence the duration of effect, concurrent infant diet influences and their long-term outcomes deserve further examination.
Pregnancy and the postnatal period are critical windows of opportunity for the prevention of metabolic diseases in the next generation. Maternal obesity or diabetes, along with poor diet, may affect the establishment of a stable, healthy intestinal microbiome in infants, with long-term health consequences. Early communication between the infant host and its gut microbiota can affect the programming of immune cells and other metabolic and biochemical pathways that may greatly affect the developmental trajectory of body weight. Bacteria-driven inflammation can reduce the abundance of other bacteria that compete with the proinflammatory pathogens, promoting organisms that may increase the ability of the gut microbiota to extract otherwise indigestible dietary polysaccharides. Alternatively, enteroendocrine cells of the gut modify or secrete a variety of bioactive peptides and fatty acids, all known to be connected to food intake, lipid storage and energy homeostasis, which can be influenced by microbial metabolites. At present, there are no well-controlled longitudinal studies of the microbiome in infants of women with diabetes during pregnancy (a growing population). Microbiota specific for maternal diabetes rather than obesity may emerge in the infant as a separate signature altered by hyperglycaemia that elicits additional risk factors for infant health.
We thank R. C. Janssen (Department of Pediatrics, University of Colorado Anschutz Medical Campus) for help with editing the manuscript and all members of the Friedman laboratory for insightful discussions.
This work was supported by the National Institutes of Health, the American Diabetes Association and the Colorado Nutrition and Obesity Research Center (NORC).
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
All authors researched, wrote, contributed to discussion and reviewed and/or edited the manuscript. All authors approved the final version of the manuscript.
- 32.Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J (2014) The placenta harbors a unique microbiome. Sci Transl Med 6:237ra265Google Scholar
- 48.Matias SL, Dewey KG, Quesenberry CP Jr, Gunderson EP (2014) Maternal prepregnancy obesity and insulin treatment during pregnancy are independently associated with delayed lactogenesis in women with recent gestational diabetes mellitus. Am J Clin Nutr 99:115–121CrossRefPubMedPubMedCentralGoogle Scholar
- 86.Wang YD, Chen WD, Yu D, Forman BM, Huang W (2011) The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 54:1421–1432CrossRefPubMedPubMedCentralGoogle Scholar
- 90.Lindsay KL, Brennan L, Kennelly MA et al (2015) Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. Am J Obstet Gynecol 212:496.e491-411Google Scholar